Literature DB >> 25349802

Intraocular pressure-lowering effects of commonly used fixed combination drugs with timolol in the management of primary open angle glaucoma.

Murat Atabey Ozer1, Mutlu Acar2, Cem Yildirim3.   

Abstract

AIM: To evaluate intraocular pressure (IOP)-lowering effect and ocular tolerability of brimonidine/timolol, dorzolamide/timolol and latanoprost/timolol fixed combination therapies in the management of primary open angle glaucoma.
METHODS: Each drug was administered for two months, after which a circadian tonometric curve was recorded using a Goldmann applanation tonometer. Ocular discomfort (conjunctival hyperemia, burning or stinging, foreign body sensation, itching, ocular pain) of each eye was assessed by the subject on a standardized ocular discomfort scale.
RESULTS: Among the three study groups, there were no significant differences in the mean baseline IOP measurements, mean 2(nd) mo IOP measurements, and mean (%) change of IOPs from baseline. Among the three study groups, there were no significant differences in the mean IOP measurements obtained at circadian tonometric curves at baseline and at two months controls. In sum brimonidine/timolol, dorzolamide/timolol and latanoprost/timolol fixed combination therapies showed similar effects on IOP levels.
CONCLUSION: Brimonidine/timolol, dorzolamide/timolol and latanoprost/timolol fixed combination therapies showed similar lowering efficaties on IOP levels whereas there was no any difference between each other.

Entities:  

Keywords:  Intraocular pressure; brimonidine/timolol; dorzolamide/timolol; latanoprost/timolol; primary open angle glaucoma

Year:  2014        PMID: 25349802      PMCID: PMC4206890          DOI: 10.3980/j.issn.2222-3959.2014.05.17

Source DB:  PubMed          Journal:  Int J Ophthalmol        ISSN: 2222-3959            Impact factor:   1.779


  19 in total

1.  A double-masked randomized crossover study comparing the effect of latanoprost/timolol and brimonidine/timolol fixed combination on intraocular pressure and ocular blood flow in patients with primary open-angle glaucoma or ocular hypertension.

Authors:  Anton Hommer; Philipp Sperl; Hemma Resch; Alina Popa-Cherecheanu; Chunyan Qiao; Leopold Schmetterer; Gerhard Garhöfer
Journal:  J Ocul Pharmacol Ther       Date:  2012-07-09       Impact factor: 2.671

2.  Safety and efficacy of monotherapy change to fixed combination (travoprost 0.004%/timolol 0.5%) in 6 months follow up period.

Authors:  Zdravko Mandić; Katia Novak-Laus; Lovro Bojić; Smiljka Popović-Suić; Miroslav Ekert; Vukosava Maricić Dosen; Goran Pelcić; Damira Clementi; Davor Dobutović; Dubravka Biuk; Renata Iveković; Zeljko Kovacić; Josip Pavan; Nikola Susić; Mia Zorić Geser; Iva Krolo; Freja Barisić; Alenka Jurić-Miletić; Katarina Kapeli Dogan; Martina Tomić; Suzana Kovacević
Journal:  Acta Clin Croat       Date:  2010-12       Impact factor: 0.780

3.  Comparison of the effects of dorzolamide/timolol and latanoprost/timolol fixed combinations upon intraocular pressure and progression of visual field damage in primary open-angle glaucoma.

Authors:  B Pajic; B Pajic-Eggspuehler; I O Häfliger
Journal:  Curr Med Res Opin       Date:  2010-09       Impact factor: 2.580

4.  Comparison of fixed combinations of dorzolamide/timolol and brimonidine/timolol in patients with primary open-angle glaucoma.

Authors:  Gokhan Gulkilik; Ersin Oba; Mahmut Odabası
Journal:  Int Ophthalmol       Date:  2011-12-30       Impact factor: 2.031

5.  Travoprost 0.004%/timolol 0.5%-fixed combination with and without benzalkonium chloride: a prospective, randomized, doubled-masked comparison of safety and efficacy.

Authors:  Y Kitazawa; P Smith; N Sasaki; S Kotake; K Bae; Y Iwamoto
Journal:  Eye (Lond)       Date:  2011-06-24       Impact factor: 3.775

6.  Comparing the fixed combination brimonidine-timolol versus fixed combination dorzolamide-timolol in patients with elevated intraocular pressure.

Authors:  Enyr S Arcieri; Rafael S Arcieri; Ana C A Pereira; Eduardo G V Andreo; Ioná G A Finotti; Wanderley F Sá Filho
Journal:  Curr Med Res Opin       Date:  2007-04       Impact factor: 2.580

7.  Trabeculectomy in the 21st century: a multicenter analysis.

Authors:  James F Kirwan; Alastair J Lockwood; Peter Shah; Alex Macleod; David C Broadway; Anthony J King; Andrew I McNaught; Pavi Agrawal
Journal:  Ophthalmology       Date:  2013-09-23       Impact factor: 12.079

8.  An eight-week, multicentric, randomized, interventional, open-label, phase 4, parallel comparison of the efficacy and tolerability of the fixed combination of timolol maleate 0.5%/brimonidine tartrate 0.2% versus fixed combination of timolol maleate 0.5%/dorzolamide 2% in patients with elevated intraocular pressure.

Authors:  Marcelo Hatanaka; Daniel E Grigera; Wilma L Barbosa; Marcelo Jordao; Remo Susanna
Journal:  J Glaucoma       Date:  2008-12       Impact factor: 2.503

9.  Lifetime risk of blindness in open-angle glaucoma.

Authors:  Dorothea Peters; Boel Bengtsson; Anders Heijl
Journal:  Am J Ophthalmol       Date:  2013-08-07       Impact factor: 5.258

Review 10.  Managing adverse effects of glaucoma medications.

Authors:  Kenji Inoue
Journal:  Clin Ophthalmol       Date:  2014-05-12
View more
  3 in total

1.  Therapeutic Effects of Hab Shabyar on Open-Angle Glaucoma: A Double-Blinded, Randomized, Placebo-Controlled Trial.

Authors:  Ebrahim Khalil-BaniHabib; Ali Mostafai; Seyyed Mohammad Bagher Fazljou; Ghadir Mohammdi
Journal:  Galen Med J       Date:  2019-01-01

2.  Automatic method of analysis and measurement of additional parameters of corneal deformation in the Corvis tonometer.

Authors:  Robert Koprowski
Journal:  Biomed Eng Online       Date:  2014-11-19       Impact factor: 2.819

3.  Selective Laser Trabeculoplasty vs. Fixed Combinations with Timolol in Practice: A Replacement Study in Primary Open Angle Glaucoma.

Authors:  Ali Kutlay Tufan; İsmail Umut Onur; Fadime Ulviye Yiğit; Ahmet Ağaçhan; Şenay Aşık Nacaroğlu
Journal:  Turk J Ophthalmol       Date:  2017-08-15
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.